Liver transplantation is aptly described as the only curative treatment for cirrhosis and cirrhosis with co-morbid hepatocellular carcinoma (HCC). Its utility in the management of various other primary and secondary liver cancers is gaining traction rapidly, with more thorough assessments on broader populations continuing to emerge. Most prominently, this includes colorectal cancer liver metastasis (CRLM), cholangiocarcinoma (CCA), neuroendocrine tumors (NETs), and more. Furthermore, despite being a well described treatment for HCC for many years, growing evidence supports a change in oncological strategy for HCC, with broadened selection criteria and more advanced systemic and locoregional therapies available. Our review aims to describe the evidence supporting the expansion of indications and selection criteria for liver transplantation in various oncologic indications of primary and secondary liver tumors.
肝移植被恰当地描述为治疗肝硬化及肝硬化合并肝细胞癌（HCC）的唯一根治性手段。其在多种其他原发性和继发性肝癌治疗中的应用正迅速获得关注，针对更广泛人群的更全面评估持续涌现。最显著的例子包括结直肠癌肝转移（CRLM）、胆管癌（CCA）、神经内分泌肿瘤（NETs）等。此外，尽管肝移植作为HCC的治疗方法已被详细描述多年，但越来越多的证据支持对HCC的肿瘤治疗策略进行调整，包括拓宽选择标准以及应用更先进的全身性和局部区域疗法。本综述旨在阐述支持扩大肝移植在各类原发性和继发性肝脏肿瘤适应症及选择标准方面的证据。
肿瘤(癌症)患者之家